ALDX Financials: Income Statement, Balance Sheet & Cash Flow

NodeGuardian · 2026-03-02T18:16:20+00:00

The article analyzes Aldeyra Therapeutics' financial health, highlighting low earnings quality, poor interest coverage, and significant losses in income and EBITDA, along with substantial R&D expenditures for fiscal year 2025.

NodeGuardian

2026-03-02 18:16:20

Abstract generation in progress

This article provides a detailed financial overview of Aldeyra Therapeutics (ALDX), including its income statement, balance sheet, cash flow statement, and key financial ratios for both annual and quarterly periods. The analysis highlights the company’s financial health signals, such as low earnings quality (0.99x) and at-risk interest coverage (-18.5x), indicating potential concerns regarding cash generation and debt servicing ability. Key metrics like net income (-$33.8M), EBITDA (-$35.0M), and R&D spending ($25.7M) for fiscal year 2025 are presented, along with year-over-year changes and FAQs about the company’s profitability and financial performance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.